HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

  • David Straus
  • , John Radford
  • , Joseph Connors
  • , Won Seog Kim
  • , Andrea Gallamini
  • , Radhakrishnan Ramchandren
  • , Jonathan Friedberg
  • , Ranjana Advani
  • , Martin Hutchings
  • , Andrew Evens
  • , Piotr Smolewski
  • , Kerry Savage
  • , Nancy Bartlett
  • , Hyeon Seok Eom
  • , Jeremy Abramson
  • , Cassie Dong
  • , Frank Campana
  • , Keenan Fenton
  • , Markus Puhlmann
  • , Stephen Ansell

Research output: Chapter in Book/Conference proceeding › Conference contribution › peer-review

Fingerprint

Dive into the research topics of 'HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science